

PERSONAL DATA:

Name : Zhong-Zhe Lin
Born : June 23, 1971 in Tainan, Taiwan
Gender : Male
Nationality : Taiwan

EDUCATION:

2010 PH.D., College of Medicine, National Taiwan University

1997 M.D., College of Medicine, National Taiwan University

EXPERIENCE:

2013-present Executive secretary, Cancer Administration and Coordination Center, National Taiwan University Hospital

2012-present Chief, Chemotherapy Room and Oncology Clinics, National Taiwan University Hospital

2004-present Attending physician, Department of Oncology, National Taiwan University Hospital

2010-present Assistant professor, Department of Internal Medicine, College of Medicine, National Taiwan University

2010-2012 Chief, Huwei Region, National Taiwan University Hospital Yun-Lin Branch

2009-2012 Director, Department of Oncology, National Taiwan University Hospital Yun-Lin Branch

2003-2004 Attending physician, Department of Oncology, Tao-Yuan General Hospital

2000-2003 Fellow, Cancer Research Center, National Taiwan University College of Medicine

2000-2003 Chief Resident, Department of Oncology and Internal Medicine (Hematology), National Taiwan University Hospital

1997-2000 Resident, Department of Internal Medicine, National Taiwan University Hospital

1996-1997 Intern, National Taiwan University Hospital

PROFESSIONAL MEMBERSHIP:

2006-present Member, American Association of Cancer Research

2004-present Member, American Society of Clinical Oncology

2002-present Member, Hematology Society of Taiwan

2000-present Member, Chinese Oncology Society

2000-present Member, Taiwan Society of Internal Medicine

1997-present Member, Formosan Medical Association

JOURNAL REVIEWER:

2009-present Journal of Gastroenterology and Hepatology

2010-present Asia-Pacific Journal of Clinical Oncology

2011-present Journal of Formosan Medical Association

2012-present ISRN Hepatology

2012-present Journal of Clinical Oncology

2012-present Cancer

2012-present 癌醫雜誌(中華民國癌症醫學會)

2013-present British Journal of Cancer

2013-present Hepatology International

JOURNAL EDITORIAL BOARD:

2013-present Advance in Medicine

PUBLICATIONS:

1. Huang CL, **Lin ZZ**, Su IJ, Chao TY, Tien HF, Chang MC, Huang MC, Kao WY, Tang JL, Yeh KH, Wang CH, Hsu CH, Liu MY, Cheng AL. Combination of 13-cis Retinoic Acid and Interferon-alpha in the Treatment of Recurrent or Refractory

Peripheral T-cell Lymphoma. Leuk Lymphoma 2002 Jul;43(7):1415-20.

2. Lu YS, Kashida Y, Kulp SK, Wang YC, Wang D, Hung JH, Tang M, **Lin ZZ**, Chen TJ, Cheng AL, Chen CS. Efficacy of OSU-HDAC42, a Novel Histone Deacetylase Inhibitor, in Murine Models of Hepatocellular Carcinoma. Hepatology 2007Oct;46(4):1119-30.
3. **Lin ZZ**, Hsu C, Chang YC, Yu CJ, Hsu CH, Lin CC, Cheng AL, Yang PC, Yang CH. Outcome of advanced nonsmall cell lung cancer patients receiving gemcitabine and weekly paclitaxel as first-line treatment. Lung Cancer 2008 May;60(2):215-21.
4. Yang CH, Yu CJ, Shih JY, Chang YC, Hu FC, Tsai MC, Chen KY, **Lin ZZ**, Huang CJ, Shun CT, Huang CL, Bean J, Cheng AL, Pao W, Yang PC. Specific EGFR mutations predict treatment outcome of stage III/IV chemo-naïve NSCLC patients receiving first-line gefitinib monotherapy. J Clin Oncol 2008 Jun;26(16):2745-53.
5. Perng RP, Yang CH, Chen YM, Chang GC, Lin MC, Hsieh RK, Chu NM, Lai RS, Su WC, Tsao CJ, Hsia TC, Chen HC, Chen CH, Huang MS, Wang JL, Ho ML, Chung CY, Yu CJ, Chang WC, Kuo HP, Yu CT, **Lin ZZ**, Kao WY. High efficacy of erlotinib in Taiwanese NSCLC patients in an expanded access program study previously treated with chemotherapy. Lung Cancer 2008 Oct;62(1):78-84.
6. **Lin ZZ**, Hsu HC, Hsu CH, Yeh PY, Huang CY, Huang YF, Chen TJ, Kuo SH, Hsu C, Jeng YM, Chung Y, Cheng AL. The Aurora kinase inhibitor VE-465 has anticancer effects in pre-clinical studies of human hepatocellular carcinoma. J Hepatol 2009 Mar;50(3):518-27.
7. Huang CL, Yang CH, Yeh KH, Hu FC, **Lin ZZ**, Wan JP, Tseng LH, Yu CJ, Cheng AL. The association of epidermal growth factor receptor (EGFR) polymorphisms and clinicopathological factors with skin rash on gefitinib use. Lung Cancer 2009 Jun;64(3):346-51.
8. Shen YC, Hsu C, Hu FC, Chang YT, **Lin ZZ**, Chang MC, Cheng AL. Nuclear overexpression of mitotic regulatory proteins in biliary tract cancer: correlation with clinicopathologic features and patient survival. Cancer Epidemiol Biomarkers Prev 2009 Feb;18(2):417-23.

9. Chen SY, Kao PC, **Lin ZZ**, Chiang WC, Feng CC. Sunitinib-induced myxedema coma. Am J Emerg Med 2009 Mar;27(3):370.e1-370.e3.
10. Shao YY, **Lin ZZ**, Liang PC, Tien YW, Cheng AL. Gastric perforation presented as empyema in a patient with pancreatic cancer receiving bevacizumab. Anticancer Res 2009 May;29(5):1665-7.
11. Yang SH, **Lin ZZ**, Kuo SH, Cheng AL. Gemcitabine-based combination chemotherapy as salvage treatment for refractory/relapsing aggressive non-Hodgkin's lymphoma. Am J Hematol 2009 Jul;84(7):457-9.
12. 邵幼雲，**林宗哲 (通訊作者)**，洪敏瑛。晚期肝細胞癌全身性治療的新趨勢。腫瘤護理雜誌 九十八年十二月第九卷增訂刊 1-9 頁。
13. Ho CL, Su WC, Hsieh RK, **Lin ZZ**, Chao TY. A Randomized, Double-blind, Parallel, Comparative Study to Evaluate the Efficacy and Safety of Ramosetron plus Dexamethasone Injection for the Prevention of Acute Chemotherapy-induced Nausea and Vomiting. Jpn J Clin Oncol 2010 Apr;40(4):294-301.
14. Hsu CH, Yang TS, Hsu C, Toh H, Hsiao LT, Chen PJ, **Lin ZZ**, Chao TY, Cheng AL. Bevacizumab in Combination With Capecitabine in Patients With Advanced or Metastatic Hepatocellular Carcinoma: Results From a Phase II Study in Asian Patients. Br J Cancer 2010 Mar;102(6):981-6.
15. Hsu CH, Shen YC, **Lin ZZ**, Chen PJ, Shao YY, Huang TC, Ding YH, Cheng AL. Phase II study of combining sorafenib with metronomic tegafur/uracil for advanced hepatocellular carcinoma. J Hepatol 2010 Jul;53(1):126-31.
16. Shao YY, Huang CC, Liang PC, **Lin ZZ (corresponding author)**. Hepatic Arterial Infusion of Chemotherapy for Advanced Hepatocellular Carcinoma. Asia-Pac J Clin Oncol 2010 June;6:80-8. (Review)
17. Shao YY, **Lin ZZ**, Hsu C, Shen YC, Hsu CH, Cheng AL. Early Alpha-Fetoprotein Response Predicts Treatment Efficacy of Anti-Angiogenic Systemic Therapy in Patients with Advanced Hepatocellular Carcinoma. Cancer 2010 Oct;116(19):4590-6.
18. Lin CC, Hsu HH, Sun CT, Shih JY, **Lin ZZ**, Yu CJ, Chen GG, Hsin MK, Lam KC,

Leung L, Yang CH, Mok T. Chemotherapy Response in East Asian Non-small Cell Lung Cancer Patients Harboring Wild-Type or Activating Mutation of Epidermal Growth Factor Receptors. J Thorac Oncol 2010 Sep;5(9):1424-9.

19. **Lin ZZ**, Jeng YM, Hu FC, Pan HW, Tsao HW, Lai PL, Lee PH, Cheng AL, Hsu HC. *Aurora B* Overexpression Is a Molecular Marker for Poor Prognosis of Hepatocellular Carcinoma. BMC Cancer 2010 Aug 28;10(1):461.
20. Yang SH, Lin CC, **Lin ZZ**, Tseng YL, Hong RL. A phase I and pharmacokinetic study of liposomal vinorelbine in patients with advanced solid tumor. Invest New Drugs. 2012 Feb;30(1):282-9. [Epub 2010 Sep 1.]
21. **Lin ZZ** and Yang CH. Current Roles and Future Perspectives of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Advanced Non-Small-Cell Lung Cancer. Eur J Clin Med Oncol 2010 Vol 2, Issue 3. (Review)
22. Shao YY, **Lin ZZ**, Chen TJ, Hsu C, Shen YC, Hsu CH, Cheng AL. High circulating endothelial progenitor levels associated with poor survival of advanced hepatocellular carcinoma patients receiving sorafenib combined with metronomic chemotherapy. Oncology. 2011 Oct 04;81(2):98-103.
23. Shao YY, Chen PJ, **Lin ZZ**, Huang CC, Ding YH, Lee YH, Hsu CH, Cheng AL. Impact of baseline hepatitis B viral DNA levels on survival of patients with advanced hepatocellular carcinoma. Anticancer Res. 2011 Nov;31(11):4007-11.
24. Kuo YH, **Lin ZZ(equal contribution)**, Yang YY, Shao YY, Shau WY, RNC Kuo, Yang CH, Lai MS. Survival of patients with small cell lung carcinoma in Taiwan. Oncology. 2012 Feb;82(1):19-24.
25. Shao YY, **Lin ZZ**, Hsu C, Lee KD, Hsiao CH, Lu YS, Huang CC, Shen YC, Hsu CH, Cheng AL. Efficacy, Safety, and Potential Biomarkers of Thalidomide plus Metronomic Chemotherapy for Advanced Hepatocellular Carcinoma. Oncology. 2012 Feb;82(1):59-66.
26. Chen WW, Shao YY, Shau WY, **Lin ZZ**, Lu YS, Chen HM, Cheng AL, Lai MS. The impact of diabetes mellitus on prognosis of early breast cancer in Asia. Oncologist. 2012 Apr;17(4):485-91. [Epub 2012 Mar 30.]

27. Shau WY, Shao YY, Yeh YC, **Lin ZZ**, Kuo RN, Hsu CH, Hsu C, Cheng AL, Lai MS. Diabetes mellitus is associated with increased mortality in patients receiving curative therapy for hepatocellular carcinoma. Oncologist. 2012 Jun;17(6):856-62. [Epub 2012 May 23.]
28. **Lin ZZ**, Hsu C, Hu FC, Shao YY, Chang DY, Yang CH, Hong RL, Hsu CH, Cheng AL. Factors Impacting Prognosis Prediction in BCLC Stage C and Child-Pugh Class A Hepatocellular Carcinoma Patients in Prospective Clinical Trials of Systemic Therapy. Oncologist. 2012 Jul;17(7):970-7. [Epub 2012 Jun 06.]
29. **Lin ZZ**, Shau WY, Shao YY, Yang YY, Kuo RN, Yang CH, Lai MS. Survival following surgery with or without adjuvant chemotherapy for stage I-IIIa non-small cell lung cancer: An East-Asian population-based study. Oncologist. 2012 Oct;17(10):1294-302. [Epub 2012 Jul 23.]
30. Shao YY, Shau WY, **Lin ZZ**, Chen HM, Kuo RN, Yang CH, Lai MS. Comparison of gefitinib and erlotinib efficacies as third-line therapy for advanced non-small-cell lung cancer. Eur J Cancer. 2013 Jan;49(1):106-14. [Epub 2012 Aug 14.]
31. Shao YY, Lu LC, **Lin ZZ**, Hsu C, Shen YC, Hsu CH, Cheng AL. Prognosis of advanced hepatocellular carcinoma patients enrolled in clinical trials can be classified by current staging systems. Br J Cancer. 2012 Nov;107(10):1672-7. [Epub 2012 Nov 6.]
32. Lu LC, Shao YY, Kuo RN, **Lin ZZ**, Yeh YC, Shau WY, Hsu CH, Cheng AL, Lai MS. Hospital volume of percutaneous radiofrequency ablation is closely associated with treatment outcomes for patients with hepatocellular carcinoma. Cancer. 2013 Mar;119(6):1210-6. [Epub 2012 Dec 4.]
33. Lee PY, Chen CL, **Lin ZZ**, Cheng AL, Chen EI, Whang-Peng J, Huang CY. The Aurora Kinases Inhibitor VE-465 is a Novel Treatment for Glioblastoma Multiforme. Oncology. 2013 June;84(6):326-35. [Epub 2013 Apr 27]
34. Liang YH, Shao YY, Chen JY, Liang PC, Cheng AL, **Lin ZZ. (corresponding author)**. Modern prospection for hepatic arterial infusion chemotherapy in malignancies with liver metastases. Int J Hepatol 2013 Apr;2013:141590. [Epub

2013 Apr 17]

35. Shao YY, Liang PC, Wu YM, Huang CC, Huang KW, Cheng JC, Hsu CH, Hsu C, Cheng AL, **Lin ZZ. (corresponding author)**. A pilot study of hepatic arterial infusion of chemotherapy for patients with advanced hepatocellular carcinoma who have failed antiangiogenic therapy. Liver Int. 2013 Oct;33(9):1413-9. [Epub 2013 May 28]
36. Shen YC, **Lin ZZ(equal contribution)**, Hsu CH, Hsu C, Shao YY, Cheng AL. Clinical trials in hepatocellular carcinoma: an update. Liver Cancer 2013 Aug; 2:345-64.
37. **Lin ZZ**, Shau WY, Hsu C, Shao YY, Yeh YC, Kuo RN, Hsu CH, Yang JC, Cheng AL, Lai MS. Radiofrequency ablation is superior to ethanol injection in early-stage hepatocellular carcinoma irrespective of tumor size. PLoS One 2013 Nov; 8(11):e80276.
38. **Lin ZZ**, Chou CH, Cheng AL, Liu WL, Cheng JC. Radiosensitization by combining an aurora kinase inhibitor with radiotherapy in hepatocellular carcinoma through cell cycle interruption. Int J Cancer 2014 Jul; 135(2):492-501.
39. Shen YC, Li CP, Yen CJ, Hsu C, Lin YL, **Lin ZZ**, Chen LT, Su WC, Chao Y, Yeh KH, Cheng AL. Phase II Multicentered Study of Low-Dose Everolimus plus Cisplatin and Weekly 24-Hour Infusion of High-Dose 5-Fluorouracil and Leucovorin as First-Line Treatment for Patients with Advanced Gastric Cancer. Oncology. 2014 Jul;87(2):104-13.
40. Chen KH, Shao YY, **Lin ZZ**, Yeh YC, Shau WY, Kuo RN, Chen HM, Lai CL, Yeh KH, Cheng AL, Lai MS. Type 2 Diabetes Mellitus Is Associated With Increased Mortality in Chinese Asian Patients Receiving Curative Surgery for Colon Cancer. Oncologist. 2014 Sep;19(9):951-8.
41. Ou DL, Chang CJ, Jeng YM, Lin YJ, **Lin ZZ**, Gandhi AK, Liao SC, Huang ZM, Hsu C, Cheng AL. Potential synergistic anti-tumor activity between lenalidomide and sorafenib in hepatocellular carcinoma. J Gastroenterol Hepatol. 2014 Dec;29(12):2021-31.
42. Liao BC, Shao YY, Chen HM, Shau WY, **Lin ZZ**, Kuo RN, Lai CL, Chen KH,

Cheng AL, Chih-Hsin Yang J, Lai MS. Comparative Effectiveness of First-Line Platinum-Based Chemotherapy Regimens for Advanced Lung Squamous Cell Carcinoma. *Clin Lung Cancer*. 2015 Mar;16(2):137-43.

43. Shao YY, Hsu CH, Yeh KH, Chen HM, Yeh YC, Lai CL, **Lin ZZ**, Cheng AL, Lai MS. Statin Use Is Associated With Improved Prognosis of Colorectal Cancer in Taiwan. *Clin Colorectal Cancer*. 2015 Sep;14(3):177-184.e4.
44. Kuo HY, **Lin ZZ(equal contribution)**, Kuo R, Shau WY, Lai CL, Yang YY, Shao YY, Hsu C, Cheng WF, Cheng AL, Yang JC, Lai MS. The Prognostic Impact of Type 2 Diabetes Mellitus on Early Cervical Cancer in Asia. *Oncologist*. 2015 Sep;20(9):1051-7.
45. Liang YH, Shao YY, Chen HM, Lai CL, **Lin ZZ**, Kuo RN, Cheng AL, Yeh KH, Lai MS. Young patients with colorectal cancer have increased risk of second primary cancers. *Jpn J Clin Oncol*. 2015 Nov;45(11):1029-35.
46. Chiang Y, Yang JC, Hsu FM, Chen YH, Shih JY, **Lin ZZ**, Lan KH, Cheng AL, Kuo SH. The Response, Outcome and Toxicity of Aggressive Palliative Thoracic Radiotherapy for Metastatic Non-Small Cell Lung Cancer Patients with Controlled Extrathoracic Diseases. *PLoS One*. 2015 Dec 31;10(12):e0145936.
47. Chen KH, Shao YY, Chen HM, Lin YL, **Lin ZZ**, Lai MS, Cheng AL, Yeh KH. Primary tumor site is a useful predictor of cetuximab efficacy in the third-line or salvage treatment of KRAS wild-type (exon 2 non-mutant) metastatic colorectal cancer: a nationwide cohort study. *BMC Cancer*. 2016 May 24;16(1):327.
48. Abou-Alfa GK, Yen CJ, Hsu CH, O'Donoghue J, Beylertgil V, Ruan S, Pandit-Taskar N, Gansukh B, Lyashchenko SK, Ma J, Wan P, Shao YY, **Lin ZZ**, Frenette C, O'Neil B, Schwartz L, Smith-Jones PM, Ohtomo T, Tanaka T, Morikawa H, Maki Y, Ohishi N, Chen YC, Agajanov T, Boisserie F, Di Laurenzio L, Lee R, Larson SM, Cheng AL, Carrasquillo JA. Phase Ib study of codrituzumab in combination with sorafenib in patients with non-curable advanced hepatocellular carcinoma (HCC). *Cancer Chemother Pharmacol*. 2017 Feb;79(2):421-9.
49. Yao ZH, Liao WY, Ho CC, Chen KY, Shih JY, Chen JS, **Lin ZZ**, Lin CC, Chih-Hsin Yang J, Yu CJ. Real-World Data on Prognostic Factors for Overall

Survival in EGFR Mutation-Positive Advanced Non-Small Cell Lung Cancer Patients Treated with First-Line Gefitinib. *Oncologist*. 2017 Sep;22(9):1075-83.

THESIS PAPER:

Lin ZZ. Exploring Molecular Targeted Therapy for Hepatoceccular Carcinoma: Focus on Aurora Kinases. Ph.D./Graduate Institute of Clinical Medicine/2010/National Taiwan University College of Medicine

MEETING ABSTRACTS:

1. **Lin ZZ**, Yeh KH, Hsu CH, Cheng AL. Weekly 24-Hour Infusion of High-Dose 5-Fluorouracil and Leucovorin (HDFL) in the Treatment of Advanced Thymic carcinoma. 2002 Annual Meeting of the Chinese Oncology Society, Taichung, Taiwan.
2. **Lin ZZ**, Hsu SC, Ko BS, Huang SY, Yao M, Tang JL, Tsay W, Chen YC, Shen MC, Wang CH, Tien HF. Chronic Lymphocytic Leukemia: clinical and cytogenetic studies. 2003 Annual Meeting of the Hematology Society of Taiwan, Kaohsiung, Taiwan.
3. Hsu CH, Yeh KH, Lin CC, **Lin ZZ**, Hsu C, Lu YS, Bu CF, Cheng AL. Multi-fractionation of paclitaxel and cisplatin by twice weekly schedule, plus weekly 24-hour infusion of high-dose 5-fluorouracil and leucovorin (twice weekly TP-HDFL) in the treatment of metastatic or recurrent esophageal cancer. *Proc Am Soc Clin Oncol* 2003;22:1336.
4. Yang CH, Yu CJ, Chen KY, **Lin ZZ**, Kuo SH, Hwang TC, Cheng AL, Yang PC. A phase II study of gefitinib as first line treatment for good performance advanced or metastatic non-small cell lung cancer in East Asian patients. *J Clin Oncol* 2006;24(18S):7167.
5. **Lin ZZ**, Hsu HC, Hsu CH, Yeh PY, Huang YF, Chen TJ, Kuo SH, Jeng YM, Cheng AL. VE-465, a novel small-molecule inhibitor of the Aurora kinases, shows anticancer effects in human hepatocellular carcinoma. 2006 Annual Meeting of the American Association of Cancer Research, Washington, D.C. (LBA-279).

6. Yang SH, Kuo SH, **Lin ZZ**, Cheng AL. Clinical Analysis of Gemcitabine in the Treatment of Relapsed or Refractory lymphoma-Single institutional experience. 2007 Annual Meeting of the Chinese Oncology Society, Taipei, Taiwan.
7. Huang CL, Yang CH, Yeh KH, Hu FC, **Lin ZZ**, Wan JP, Tseng LH, Yu CJ, Cheng AL. The association of epidermal growth factor receptor (EGFR) polymorphisms and clinicopathological factors with skin rash on gefitinib use. *J Clin Oncol* 2007;25(18S):18118.
8. Yang CH, Yu CJ, Shih JY, Tsai MC, Chen KY, **Lin ZZ**, Hsu HH, Yang PC. A Prospective Study Assessing Tumor Response of Gefitinib in Chemonaive Good Performance Advanced Stage Non-small Cell Lung Cancer (NSCLC) Patients With Different Types of Epidermal Growth Factor Receptor (EGFR) Mutations. 2007, 12th World Conference on Lung Cancer, Seoul, Korea.
9. **Lin ZZ**, Hsu C, Chang YC, Yu CJ, Hsu CH, Lin CC, Cheng AL, Yang PC, Yang CH. Outcome of advanced non-small cell lung cancer patients receiving gemcitabine and weekly paclitaxel as first-line treatment. 2007, 12th World Conference on Lung Cancer, Seoul, Korea.
10. **Lin ZZ**, Jeng YM, Hsu HC, Cheng AL. Validating Aurora B as a potential therapeutic target for human hepatocellular carcinoma. *Mol Cancer Ther* 2007; 6(12):3501S.
11. Hsu CH, Yang TS, Hsu C, H. Toh, R. Epstein, L. Hsiao, **Lin ZZ**, Cheng AL. Phase II study of bevacizumab (A) plus capecitabine (X) in patients (pts) with advanced/metastatic hepatocellular carcinoma (HCC): final report. *J Clin Oncol* 26: 2008 (May 20 suppl; abstr 4603).
12. Shen YC, Shao YY, Hsu CH, Hsu C, **Lin ZZ**, Chen PJ, Ding YH, Cheng AL. Phase II study of sorafenib plus tegafur/uracil (UFT) in patients with advanced hepatocellular carcinoma (HCC). *J Clin Oncol* 26: 2008 (May 20 suppl; abstr 15664).
13. Hsu C, Chang DY, **Lin ZZ**, Lee KD, Hsiao CH, Shen YC, Cheng AL, Hsu CH. Thalidomide plus tegafur/uracil for the treatment of advanced/metastatic hepatocellular carcinoma (HCC): A phase II single-arm study. *J Clin Oncol* 26:

2008 (May 20 suppl; abstr 15598).

14. **Lin ZZ**, Chang DY, Shao YY, Hsu CH, Hsu C, Yeh KH, Yang CH, Hong RL, Cheng AL. Prognostic factors of survival in 236 advanced hepatocellular carcinoma patients enrolled in prospective clinical trials of systemic therapy. Annual Meeting of the American Society of Clinical Oncology, Orlando, Florida 2009
15. Shao YY, **Lin ZZ**, Hu FC, Yu CJ, Shih JY, Hu WY, Chang YC, Cheng AL, Yang PC, Yang CH. Quality of life in advanced non-small cell lung cancer patients receiving first-line gefitinib monotherapy. Annual Meeting of the American Society of Clinical Oncology, Orlando, Florida 2009 (Abstract 9614).
16. Hsu C, **Lin ZZ**, Lee KD, Yeh KH, Hsiao CH, Shen YC, Chang DY, Wang SH, Hsu CH, Cheng AL. A phase II trial of thalidomide plus tegafur/uracil for patients with advanced/metastatic hepatocellular carcinoma (HCC)_Final report. Annual Meeting of the American Society of Clinical Oncology, Orlando, Florida 2009.
17. Shen YC, Hsu C, Hsu CH, **Lin ZZ**, Chen PJ, Shao YY, Huang TC, Ding YH, Cheng AL. A phase II study of sorafenib in combination with tegafur/uracil (UFT) for Asian patients with advanced hepatocellular carcinoma (HCC). Annual Meeting of the American Society of Clinical Oncology, Orlando, Florida 2009.
18. Shao YY, **Lin ZZ**, Chen TJ, Chang DY, Hsu C, Shen YC, Hsu CH, Cheng AL. Baseline level of circulating endothelial progenitors predicts progression-free survival and overall survival in advanced hepatocellular carcinoma patients treated with sorafenib plus metronomic chemotherapy. Annual Meeting of the American Association of Cancer Research 2009 (Abstract 690).
19. Shao YY, **Lin ZZ**, Hsu C, Shen YC, Hsu CH, Cheng AL. Early Alpha-Fetoprotein Response Predicts Treatment Efficacy of Anti-Angiogenic Systemic Therapy in Patients with Advanced Hepatocellular Carcinoma. EORTC-NCI-ASCO Annual Meeting on "Molecular Markers in Cancer", Brussels, Belgium 2009.
20. Ho CL, Su WC, Hsieh RK, **Lin ZZ**, Chao TY. A Randomized, Double-blind, Parallel, Comparative Study to Evaluate the Efficacy and Safety of Ramosetron plus Dexamethasone Injection for the Prevention of Acute Chemotherapy-induced Nausea and Vomiting. 20th Asia Pacific Cancer Conference, Tsukuba, Japan 2009.

21. **Lin ZZ**, Jeng YM, Hu FC, Pan HW, Tsao HW, Hsu HC, Cheng AL. Overexpression of Aurora B kinase is correlated with vascular invasion and metastasis of human hepatocellular carcinoma. Annual Meeting of the American Association of Cancer Research, Washington, D.C. 2010 (#3290)
22. Shao YY, Chen CL, Huang CC, **Lin ZZ**, Hsu CH, Cheng AL. Discordance of the immunohistochemical expression of phospho-Akt and phosphor-ERK between paired biopsy and hepatectomy specimens of hepatocellular carcinoma. Annual Meeting of the American Association of Cancer Research, Washington, D.C. 2010 (#3759)
23. Shao YY, **Lin ZZ**, Chen TJ, Hsu C, Shen YC, Cheng AL. Prognostic values of baseline circulating endothelial progenitor level for advanced hepatocellular carcinoma (HCC) patients under antiangiogenic therapy. Annual Meeting of the American Society of Clinical Oncology, Chicago, Illinois 2010 (#4063).
24. Shao YY, **Lin ZZ**, Hsu CH, Hsu C, Cheng AL. Impact of Viral Etiology on the Outcomes of Patients with Advanced Hepatocellular Carcinoma Enrolled in Prospective Clinical Trials for Systemic Therapy. American Society of Clinical Oncology Gastrointestinal Cancers Symposium 2010, Abstract 163
25. Shao YY, Hsu CH, **Lin ZZ**, Huang CC, Ding YH, Lee YH, Cheng AL. Prognostic Impact of Baseline Hepatitis B Virus (HBV) Activity on Advanced Hepatocellular Carcinoma Patients Treated with Anti-Angiogenic Therapy. The 13th Taiwan Joint Cancer Conference 2010, Taipei, Taiwan, abstract GII-02
26. Chen HM, Shau WY, Shao YY, **Lin ZZ**, Kuo RNC, Lai MS. Comparative Effectiveness of Gefitinib, Docetaxel and Pemetrexed as Second Line Salvage Treatments for Advanced Non-Small Cell Lung Cancer, a Nation Wide Cohort Study in Taiwan. The 16th Japanese Society for Pharmacoepidemiology and the 5th Asian Conference on Pharmacoepidemiology 2010.
27. Yeh KH, Shen YC, Li CP, Yen CJ, Hsu C, **Lin ZZ**, Chen LT, Su WC, Chao Y, Cheng AL. Phase II study of weekly low-dose everolimus plus weekly 24-hour infusions of cisplatin and high-dose 5-fluorouracil and leucovorin for first-line treatment in patients with advanced gastric cancers. American Society of Clinical Oncology, Gastrointestinal Cancers Symposium, San Francisco, California, 2011

28. Shao YY, Yeh YC, **Lin ZZ**, Kuo RNC, Shau WY, Hsu CH, Cheng AL, Lai MS. Impact of Hospital Volumes of Radiofrequency Ablations for Hepatocellular Carcinoma on the Treatment Outcomes. The 13th Taiwan Joint Cancer Conference 2012, Taipei, Taiwan, abstract 16th-C-7-005.
29. Shao YY, Hsu CH, **Lin ZZ**, Hsu C, Cheng AL. CUPI and CLIP Staging Systems Predict Prognosis of Advanced Hepatocellular Carcinoma Patients Treated with Anti-Angiogenic Therapy. Proceedings of American Society of Clinical Oncology 2011, Abstract e14669.
30. Lin CC, **Lin ZZ**, Lin YL, Yu CJ, Shih JY, Chen KY, Ho CC, Liao WY, Yang CH. A phase I dose defining study for MK-2206 combined with gefitinib in NSCLC population enriched with EGFR mutation. Proceedings of American Society of Clinical Oncology 2012, Abstract 96402.
31. **Lin ZZ**, Huang CY, Pan HW, Sun NY, Hsiao LP, Hsu HC, Cheng AL. LGI147, a novel small-molecule inhibitor of the mitotic kinesin Eg5, shows anticancer effects in human hepatocellular carcinoma. Annual Meeting of the American Association of Cancer Research 2012 (Abstract 1781)
32. **Lin ZZ**, Shau WY, RNC Kuo, Shao YY, Yang YY, Yang CH, Lai MS. Perioperative chemotherapy in stage III non-small cell lung cancer: An East-Asian population-based study. 140th APHA Annual Meeting 2012 (Abstract 266403).
33. **Lin ZZ**, Pan HW, Sun NY, Jeng YM, Cheng AL, Hsu HC. Osteopontin overexpression synergistically interacts with Aurora A overexpression, and is associated with tumor progression, early tumor recurrence, and poor prognosis in hepatocellular carcinoma. AACR-NCI-EORTC International Conference on "Molecular Targets and Cancer Therapeutics" Dublin, Ireland 2012 (#481)
34. **Lin ZZ**, Chou CH, Cheng AL, Cheng JC. Radiosensitization by Combining an Aurora Kinase Inhibitor with Radiotherapy in Hepatocellular Carcinoma through Cell Cycle Interruption. 22nd World Congress of the International Association of Surgeons, Gastroenterologists and Oncologists. (#585)
35. Chen KH, Shao YY, Yeh YC, Shau WY, Kuo RN, **Lin ZZ**, Chen HM, Yeh KH, Cheng AL, Lai MS. Diabetes Mellitus Increased Mortality of Patients Receiving

Curative Surgery for Early Colon Cancer. American Society of Clinical Oncology Gastrointestinal Cancers Symposium 2013, Abstract 104991.

36. **Lin ZZ**, Shau WY, Shao YY, Yeh YC, RNC Kuo, Hsu C, Hsu CH, Cheng AL, Lai MS. Survival of patients receiving radiofrequency ablation or ethanol injection for early-stage hepatocellular carcinoma. Proceedings of American Society of Clinical Oncology 2013, Abstract e15043. [J Clin Oncol 31, 2013 (suppl; abstr e15043)]
37. Ma WL, Shao YY, Hsu CH, Yeh KH, Chen HM, Yeh YC, Lai CL, **Lin ZZ**, Cheng AL, Lai MS. Regular statin users have better colorectal cancer (CRC) prognosis. Proceedings of American Society of Clinical Oncology 2013, Abstract 3554. [J Clin Oncol 31, 2013 (suppl; abstr 3554)]
38. **Lin ZZ**, Shau WY, Shao YY, Yang YY, Kuo RN, Yang CH, Lai MS. Survival following surgery with or without adjuvant chemotherapy for stage I-IIIa non-small cell lung cancer: An East-Asian population-based study. 15th World Conference on Lung Cancer, 2013. (Abstract 1235)
39. **Lin ZZ**, Kuo YH, Yang YY, Shao YY, Shau WY, Kuo RN, Yang CH, Lai MS. Survival of patients with small cell lung carcinoma in Taiwan. 15th World Conference on Lung Cancer, 2013. (Abstract 1252).
40. Abou-Alfa GK, Yen CJ, Carrasquillo JA, Hsu CH, Gansukh B, Ma J, Hollywood E, Wan PJ, Shao YY, **Lin ZZ**, Frenette C, O'Neil BH, Schwartz LH, Ohtomo T, Tanaka T, Chen YC, Ukrainskyj S, Saltz L, Lee RM, Cheng AL. Phase Ib study of RO5137382/GC33 in combination with sorafenib in patients with advanced hepatocellular carcinoma (HCC)(NCT00976170). J Clin Oncol 32, 2014 (suppl; abstr e4100).
41. Lin CC, Yu CJ, Ho CC, Chen KY, Shih JY, **Lin ZZ**, Lin YL, Liao WY, Tsai SH, Yan L, Yang JC. A phase I dose-defining study for MK-2206 combined with gefitinib in NSCLC population enriched with EGFR mutation. J Clin Oncol 32, 2014 (suppl; abstr e19013).
42. Kuo HY, **Lin ZZ**, Kuo RNC, Shau WY, Lin CL, Yang YY, Shao YY, Hsu C, Cheng WF, Cheng AL, Yang JC, Lai MS. The impact of diabetes mellitus on early cervical cancer in Asia: A population-based cohort study. J Clin Oncol 32, 2014 (suppl; abstr e16501).

43. Wu H, Liang YH, Shao YY, Chen HM, Lai CL, **Lin ZZ**, Shau WY, Yeh KH, Cheng AL, Lai MS. Risk of second primary malignancies in young patients with colorectal cancer. *J Clin Oncol* 32, 2014 (suppl; abstr e14533).
44. **Lin ZZ**, Chou CH, Cheng AL, Cheng JC. Radiosensitizing effect of Aurora kinase inhibitor VE-465 in hepatocellular carcinoma. ESMO 16th World Congress on Gastrointestinal Cancer, Barcelona 2014, Abstract 936.
45. Liang PC, Shao YY, Wu YM, Huang CC, Huang KW, Cheng JC, Hsu CH, Hsu C, Cheng AL, **Lin ZZ (Corresponding A)**. A pilot study of hepatic arterial infusion of chemotherapy for patients with advanced hepatocellular carcinoma who have failed antiangiogenic therapy. ESMO 16th World Congress on Gastrointestinal Cancer, Barcelona 2014, Abstract 971.
46. **Lin ZZ**, Chao Y, Shen YC, Chen BB, Hsu CH, Shao YY, Lee YH, Hsu C, Cheng AL. Axitinib as second-line treatment for advanced hepatocellular carcinoma (HCC): preliminary results of a phase 2 trial. The 5th Asia-Pacific Primary Liver Cancer Expert Meeting, Taipei, 2014.
47. **Lin ZZ**, Hsu C, Tsai YC, Sun NY, Cheng WF, Yeh SH, Chen CS, Chen PJ, Cheng AL. Synergistic antitumor effects between telomerase-specific replication competent oncolytic adenovirus (Telomelysin) and histone deacetylase inhibitor (AR42) in human hepatocellular carcinoma cells. The 9th International Conference on Oncolytic Virus Therapeutics, Boston, 2015.
48. **Lin ZZ**, Liang PC, Huang CC, Hu FC, Shao YY, Shen YC, Hsu C, Hsu CH, Cheng AL. Computed tomography response criteria in patients with advanced hepatocellular carcinoma receiving anti-angiogenic therapy in clinical trials. The 6th Asia-Pacific Primary Liver Cancer Expert Meeting, Osaka, 2015.
49. **Lin ZZ**, Jeng YM, Hsu C, Tsai IL, Chen KY, Hu FC, Hsu CH, Hsu HC, Cheng AL. Expression of FGF19/FGFR4 related biomarkers in hepatocellular carcinoma. Annual Meeting of the American Association of Cancer Research, New Orleans. 2016 (#3131)
50. **Lin ZZ**, Hsu C, Tsai YC, Sun NY, Cheng WF, Yeh SH, Chen CS, Chen PJ, Cheng AL. Inhibition of Akt phosphorylation is involved in therapeutic synergy between

telomerase-specific replication competent oncolytic adenovirus (Telomelysin) and histone deacetylase inhibitor (AR42) in human hepatocellular carcinoma. The International Liver Conference, Amsterdam, 2017 (ILC2017-RS-2973).